ATE228166T1 - Bifunktionelles protein, herstellung und verwendung - Google Patents

Bifunktionelles protein, herstellung und verwendung

Info

Publication number
ATE228166T1
ATE228166T1 AT95918576T AT95918576T ATE228166T1 AT E228166 T1 ATE228166 T1 AT E228166T1 AT 95918576 T AT95918576 T AT 95918576T AT 95918576 T AT95918576 T AT 95918576T AT E228166 T1 ATE228166 T1 AT E228166T1
Authority
AT
Austria
Prior art keywords
sub
hinge region
zeta
bifunctional protein
joined
Prior art date
Application number
AT95918576T
Other languages
English (en)
Inventor
Bernd Groner
Dirk Moritz
Original Assignee
Bernd Groner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernd Groner filed Critical Bernd Groner
Application granted granted Critical
Publication of ATE228166T1 publication Critical patent/ATE228166T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95918576T 1994-05-02 1995-04-20 Bifunktionelles protein, herstellung und verwendung ATE228166T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810244 1994-05-02
PCT/EP1995/001494 WO1995030014A1 (en) 1994-05-02 1995-04-20 Bifunctional protein, preparation and use

Publications (1)

Publication Number Publication Date
ATE228166T1 true ATE228166T1 (de) 2002-12-15

Family

ID=8218248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95918576T ATE228166T1 (de) 1994-05-02 1995-04-20 Bifunktionelles protein, herstellung und verwendung

Country Status (18)

Country Link
US (1) US6984382B1 (de)
EP (1) EP0758394B1 (de)
JP (1) JP3742103B2 (de)
KR (1) KR100373813B1 (de)
AT (1) ATE228166T1 (de)
AU (1) AU694222B2 (de)
CA (1) CA2188422C (de)
DE (1) DE69528894T2 (de)
DK (1) DK0758394T3 (de)
ES (1) ES2185705T3 (de)
FI (1) FI119191B (de)
IL (1) IL113530A0 (de)
NO (1) NO316923B1 (de)
NZ (1) NZ285395A (de)
PT (1) PT758394E (de)
TW (1) TW428026B (de)
WO (1) WO1995030014A1 (de)
ZA (1) ZA953440B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU694222B2 (en) 1994-05-02 1998-07-16 Bernd Groner Bifunctional protein, preparation and use
WO1997024446A2 (en) * 1995-12-29 1997-07-10 Chiron Corporation Gene delivery vehicle-targeting ligands
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE10121113A1 (de) * 2001-04-28 2002-10-31 Gabriele Pecher Genmodifizierte YT Zelllinie und ihre Verwendung
ES2925912T3 (es) 2004-07-10 2022-10-20 The Institute For Cancer Res Líneas de células asesinas naturales humanas genéticamente modificadas
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
UA97469C2 (uk) 2005-07-25 2012-02-27 Емерджент Продакт Дівелопмент Сіетл, Елелсі Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
MX363905B (es) * 2006-06-12 2019-04-08 Aptevo Res & Development Llc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2008045437A2 (en) * 2006-10-09 2008-04-17 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
DK2614077T3 (en) 2010-09-08 2016-11-21 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
JP6389166B2 (ja) 2012-05-07 2018-09-12 トラスティーズ・オブ・ダートマス・カレッジ 抗ｂ７−ｈ６抗体、融合タンパク質、及びこれらを使用する方法
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
HUE046961T2 (hu) 2013-02-20 2020-04-28 Univ Pennsylvania Rák kezelése humanizált EGFRVIII elleni kiméra antigénreceptor alkalmazásával
TW201446794A (zh) 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
EP2970426B1 (de) 2013-03-15 2019-08-28 Michael C. Milone Anzielung zytotoxischer zellen mit chimären rezeptoren für eine adoptive immuntherapie
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
BR112016013187A2 (pt) 2013-12-19 2017-09-26 Novartis Ag receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3097117B1 (de) 2014-01-21 2023-10-04 Novartis Ag Verbessertes antigen mit car-t-zellfähigkeit durch co-einführung von co-stimulatorischen molekülen
MX395149B (es) 2014-04-07 2025-03-24 Novartis Ag Terapias de combinación que comprenden un receptor quimérico de antígeno cd19 para el cáncer.
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
AR101829A1 (es) 2014-07-21 2017-01-18 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
MX2017001011A (es) 2014-07-21 2018-05-28 Novartis Ag Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
KR20210149228A (ko) 2014-09-17 2021-12-08 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
EP4036109A3 (de) 2014-12-29 2022-10-12 Novartis AG Verfahren zur herstellung von zellen mit expression des chimären antigenrezeptors
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN119925616A (zh) 2015-04-08 2025-05-06 诺华股份有限公司 Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TWI859112B (zh) 2015-07-21 2024-10-21 瑞士商諾華公司 改良免疫細胞之功效及擴展之方法
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
CN108367004B (zh) 2015-09-21 2022-09-13 阿帕特夫研究和发展有限公司 Cd3结合多肽
HK1257295A1 (zh) 2015-12-04 2019-10-18 Novartis Ag 用於免疫肿瘤学的组合物和方法
EP3393504B1 (de) 2015-12-22 2025-09-24 Novartis AG Mesothelin-spezifischer chimärischer antigenrezeptor (car) und antikörper gegen pd-l1zur kombinierten verwendung bei therapie gegen krebs
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
CN110225927B (zh) 2016-10-07 2024-01-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
EP4043485A1 (de) 2017-01-26 2022-08-17 Novartis AG Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
CN110832075A (zh) 2017-03-22 2020-02-21 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
US11999802B2 (en) 2017-10-18 2024-06-04 Novartis Ag Compositions and methods for selective protein degradation
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
CA3089051A1 (en) 2018-01-22 2019-07-25 Endocyte, Inc. Methods of use for car t cells
US12240870B2 (en) 2018-02-23 2025-03-04 Purdue Research Foundation Sequencing method for CAR T cell therapy
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
CN110627895B (zh) * 2018-06-25 2021-03-23 北京大学 肺癌特异性tcr及其分析技术和应用
MX2021002316A (es) 2018-08-31 2021-07-15 Invectys SA Receptores de antígeno quimérico frente a múltiples isoformas de hla-g.
US20220221455A1 (en) * 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
CN114761037A (zh) 2019-11-26 2022-07-15 诺华股份有限公司 结合bcma和cd19的嵌合抗原受体及其用途
WO2022182891A1 (en) 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260880A3 (de) 1986-09-11 1990-03-07 Dana-Farber Cancer Institute, Inc. Verfahren zur Auslösung der Zytotoxizität
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
FI105320B (fi) 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
EP0556345B2 (de) 1990-10-31 2005-10-12 Cell Genesys, Inc. Nützliche retrovirale vektoren für die gentherapie
DK0517895T3 (da) * 1990-12-14 1997-04-07 Univ California Kimæriske kæder til receptorforbundne signaltransduktionsveje
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) * 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
FR2672901B1 (fr) 1991-02-15 1994-09-30 Immunotech Sa Nouvelles molecules de dna recombinants codant pour une chaine du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
AU1453792A (en) 1991-02-27 1992-10-06 Regents Of The University Of California, The Targeting complex mediated immunogenicity
IL101147A (en) 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5939531A (en) 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
AU2462392A (en) 1992-04-14 1993-11-18 British Biotech Pharmaceuticals Limited Induction of CTL responses
AU694222B2 (en) 1994-05-02 1998-07-16 Bernd Groner Bifunctional protein, preparation and use

Also Published As

Publication number Publication date
NO316923B1 (no) 2004-06-28
ZA953440B (en) 1995-11-02
FI964311A0 (fi) 1996-10-25
AU694222B2 (en) 1998-07-16
KR100373813B1 (ko) 2003-10-08
DK0758394T3 (da) 2003-03-03
PT758394E (pt) 2003-04-30
AU2446995A (en) 1995-11-29
DE69528894T2 (de) 2003-03-27
EP0758394B1 (de) 2002-11-20
NO964641D0 (no) 1996-11-01
NZ285395A (en) 1998-10-28
US6984382B1 (en) 2006-01-10
JP3742103B2 (ja) 2006-02-01
EP0758394A1 (de) 1997-02-19
FI964311L (fi) 1996-10-25
TW428026B (en) 2001-04-01
DE69528894D1 (de) 2003-01-02
WO1995030014A1 (en) 1995-11-09
NO964641L (no) 1996-11-01
JPH09512176A (ja) 1997-12-09
CA2188422C (en) 2011-03-15
CA2188422A1 (en) 1995-11-09
FI119191B (fi) 2008-08-29
IL113530A0 (en) 1995-07-31
ES2185705T3 (es) 2003-05-01

Similar Documents

Publication Publication Date Title
DE69528894D1 (de) Bifunktionelles protein, herstellung und verwendung
NO963018L (no) CTLA4-mutantmolekyler og anvendelser derav
ES2093623T3 (es) Receptores monovalentes y oligovalentes, bioespecificos y oligoespecificos, su preparacion y empleo.
WO2000023573A3 (en) Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
KR927003847A (ko) 수용체-결합된 신호 변환 경로를 위한 키메라 사슬
ATE170562T1 (de) Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen
EP1878746A3 (de) Humane monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor
WO2002077029A3 (en) Cd19-specific redirected immune cells
IE890182L (en) Cloned genes encoding IG-CD4 fusion proteins and the use thereof
GR3030415T3 (en) Platelet activating factor antagonists.
IL112390A0 (en) A cell which expresses chimeric receptors, DNA and vectors encoding said receptors and pharmaceutical compositions containing the same
HUT77253A (hu) CD4-csalireceptorokat és rokonszerkezetű molekulákat hordozó sejtek és alkalmazásuk
WO1999042127A3 (en) Receptor derived peptides as modulators of receptor activity
WO1996021028A3 (en) Soluble heterodimeric t cell receptors and their antibodies
AU5173996A (en) Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels
DE69631624D1 (de) Antikörper gegen menschliches restrictin
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
RU94026276A (ru) Рецепторы интерлейкина-12 и антител
NO940797L (no) Reseptorderivater som har bindingseter for human-rhinovirus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0758394

Country of ref document: EP